Background
==========

Uric acid (UA) is the end product of purine metabolism in human and hyperuricemia is a known risk factor for gout, hypertension, renal disease, and metabolic syndrome \[[@B1]\]. While high levels of UA are considered as a pathogenic factor, UA also possesses antioxidant properties and epidemiological studies have shown that reduced concentrations of UA are linked to neurodegenerative disorders such as multiple sclerosis, Parkinson's disease (PD), Alzheimer's disease and optic neuritis \[[@B2]\], supporting the potential neuroprotective effect of UA. In addition to human epidemiological studies, the neuroprotective effect of UA has also been identified in cellular and animal models for PD \[[@B3]-[@B5]\].

Physiologically, UA concentrations are an order of magnitude lower in cerebral tissue compared to blood UA levels \[[@B6]\]. Interestingly, studies have reported that CSF and blood UA levels are correlated \[[@B5],[@B7]\]. Furthermore, increased plasma and striatum levels of UA have been detected in rats given intraperitoneal injections of UA \[[@B4]\]. These reports suggest that UA in the brain, and CSF, might be dependent upon the level of UA in the blood, while UA could also be synthesized locally in the brain \[[@B5]\]. However, due to a significant lack of information regarding the key molecules involved, the origin of brain UA, or how UA homeostasis is maintained in brain parenchyma and CSF, remains largely unknown.

Multiple urate transporters in the kidney are involved in the regulation of serum UA levels (SUA). Renal urate reabsorption is mainly mediated by urate transporter 1 (URAT1) on the apical side of the renal proximal tubular cells, and the voltage-driven urate transporter (URATv1/Glut9) on the basolateral side \[[@B8],[@B9]\]. In addition, the ATP-binding cassette transporter, sub-family G, member 2 (ABCG2), has been identified as another transporter that regulates SUA \[[@B10]-[@B12]\]. Intriguingly, while the presence of these transporters in the brain has been demonstrated in several studies \[[@B13]-[@B16]\], detailed spatial information of the specific localization pattern of these vital transporters is generally lacking.

In the present study, we investigated the distribution of URAT1 in mouse brain by immunohistochemical analysis using an anti-URAT1 antibody \[[@B17]\], the specificity of which was confirmed using a URAT1 knockout mouse.

Methods
=======

Animals
-------

Male C57BL/6 J mice (Sankyo Laboratories, Tokyo, Japan) and homozygous URAT1 knockout mice \[[@B17]\] were maintained under a 14:10 light cycle with free access to food and water. For this study, 8--10 mice were used in each group. All animal experiments were carried out in accordance with the guidelines for animal experimentation in Teikyo University and the project was approved by the local committee.

Immunohistochemistry of URAT1 in mouse brain
--------------------------------------------

Nine-week-old C57BL/6 J male mice and URAT1 knockout male mice were anesthetized by pentobarbital injection (50 mg/kg, i.p.) and perfused intra-cardially with 4% paraformaldehyde in HEPES buffer (30 mM HEPES, 100 mM NaCl, 2 mM CaCl~2~, pH 7.5). Brains were removed and post-fixed overnight (for paraffin embedding) or 3 h (for cryoprotection) at 4°C in the same fixative. Brains were then cut coronally or sagittally and prepared for paraffin embedding or cryoprotection. For paraffin embedding, tissues were dehydrated in a graded series of alcohols, cleared with Hemo-De (a Xylene substitutive, FALMA, Tokyo, Japan), embedded in Paraplast (Sigma, St. Louis, MO, USA), and sectioned at 3 μm. After deparaffinization and rehydration, endogenous peroxidase activity was blocked by 0.03% H~2~O~2~ methanol solution for 10 min. Sections were then incubated for 1 h at room temperature in blocking solution containing 2% bovine serum albumin (Jackson ImmunoResearch, West Grove, PA, USA) in 0.01 M PBS with 0.02% Tween-20, followed by incubation with primary antibodies diluted in blocking solution at 4°C overnight (anti-URAT1 antibody, 1:5000). Immunostaining was visualized with EnVision™ Systems and DAB+, Liquid (Dako Japan, Tokyo Japan). To prepare cryostat sections (12 μm), post-fixed brains were cryoprotected in 15% sucrose (wt/vol) in PBS for 48 h at 4°C, embedded in Tissue-Tek OCT compound (Sakura Finetek Japan, Tokyo, Japan), and frozen on dry ice. Cryostat sections were fixed in methanol (−20°C, 30 min) and acetone (4°C, 10 min), incubated for 1 h at room temperature in blocking solution containing 5% normal goat serum (Cedarlane, Ontario, Canada) in 0.01 M PBS with 0.1% Triton X-100, followed by incubation with primary antibodies diluted in blocking solution at 4°C overnight. The following antibodies were used for double staining: anti-URAT1, 1:1000; anti-acetylated-α-tubulin (6-11B-1, IgG2b, Sigma), 1:500. Sections were then incubated with Alexa 488- or Alexa 594-conjugated secondary antibodies (Life Technologies, Tokyo, Japan) for 1 h at room temperature and mounted with Vectashield containing DAPI (Vector Laboratories, Burlingame, CA, USA).

Image acquisition
-----------------

DAB-stained sections were scanned with a NanoZoomer 2.0-HT slide scanner (Hamamatsu Photonics, Hamamatsu, Japan). For immunofluorescence experiments, single-plane images were captured using a Nikon A1 confocal microscope (Nikon, Tokyo, Japan) with identical settings.

Results
=======

Distribution of URAT1 in mouse brain
------------------------------------

To investigate the distribution of URAT1 in the mouse brain, we performed immunohistochemistry upon adult mouse brain paraffin coronal sections by using a rabbit polyclonal anti-mouse URAT1 antibody \[[@B17]\]. Strong URAT1 immunoreactivity was detected in ependymal cells lining the lateral ventricle (Figure [1](#F1){ref-type="fig"}A and B), dorsal third ventricle (Figure [1](#F1){ref-type="fig"}C), ventral third ventricle (Figure [1](#F1){ref-type="fig"}D), aqueduct (Figure [1](#F1){ref-type="fig"}E) and fourth ventricle (Figure [1](#F1){ref-type="fig"}F). These patterns of immunoreactivity were not observed in sections from the URAT1 knockout mice (Figure [1](#F1){ref-type="fig"}G--L). Weaker immunostaining in the brain parenchyma, and the choroid plexus of the lateral and dorsal third ventricles, appeared to be non-specific, since similar staining was observed in sections from the knockout mice (Figure [1](#F1){ref-type="fig"}).

![**Distribution of URAT1 in mouse brain.** Paraffin sections from nine-week-old WT (**A--F**, coronal section; **M--O**, sagittal section) and URAT1 KO (**G--L**, coronal section) mice were stained with a polyclonal antibody to URAT1 (anti-URAT1 antibody) and counterstained with hematoxylin. Red squares in the diagrams indicate the region of the images while the lower panels show magnified images around the ependymal cells (represented as dotted squares in the upper panels). Images **(B--D)**, **(H--J)** or **(M--N)** were obtained from the same sections, respectively. Scale bars, 200 μm and 10 μm in top and bottom row of **(L)**, respectively; 200 μm in **(M--O)**. LV, lateral ventricle; V3V, ventral third ventricle; D3V, dorsal third ventricle, AQ, aqueduct; 4V, fourth ventricle.](2045-8118-10-31-1){#F1}

Ependymal cells form an epithelial layer that lines the cerebral ventricles and function as a barrier between the cerebrospinal fluid and the brain parenchyma. Morphologically, these cells possess cilia and microvilli on their apical surfaces. At higher magnification, dense URAT1 positive signals were detected in cilia-like protrusions (Figure [1](#F1){ref-type="fig"}A--F, lower panels). URAT1 localization along the ventral third ventricle was restricted to the ependymal cells that line the upper part of the ventral third ventricle and could not be observed in the non-ciliated tanycytes, which are located in the lower part of the ventral third ventricle (Figure [1](#F1){ref-type="fig"}D).

URAT1-distribution in the ventricles was also examined in sagittal sections, showing continuous expression in the lateral ventricle (Figure [1](#F1){ref-type="fig"}M), dorsal third ventricle (Figure [1](#F1){ref-type="fig"}M), aqueduct (Figure [1](#F1){ref-type="fig"}N and O) and fourth ventricle (Figure [1](#F1){ref-type="fig"}N). These results suggest that URAT1 is expressed in ciliated-ependymal cells in the ventricular system of the mouse brain.

Expression levels of URAT1 differ between ventricles
----------------------------------------------------

Interestingly, URAT1 immunoreactivity in the aqueduct was prominent compared to the other ventricular regions (Figure [1](#F1){ref-type="fig"}E,N,O). To confirm this point, we performed immunofluorescence staining of frozen sections using the same anti-URAT1 antibody. Similar to the results gleaned from paraffin section immunohistochemistry, intense immunoreactivity was distributed in the ependymal cells of multiple ventricles, but not at the choroid plexus or in the brain parenchyma (Figure [2](#F2){ref-type="fig"}A--F). In the ventral third ventricle, URAT1-positive signals were restricted to the upper part of the ventral third ventricle and not detected in tanycytes of the lower part of the ventral third ventricle (Figure [2](#F2){ref-type="fig"}D). Within the ventricular system, the strongest signal was observed in the aqueduct (Figure [2](#F2){ref-type="fig"}E), indicating that expression levels of URAT1 differ between ventricles.

![**Expression levels of URAT1 differ between ventricles. (A--F)** Frozen coronal sections from nine-week-old WT mice were stained with anti-URAT1 (red) and DAPI (blue) and imaged by confocal microscopy. Scale bar, 200 μm.](2045-8118-10-31-2){#F2}

URAT1 localizes to the apical surface, including the cilia of ependymal cells
-----------------------------------------------------------------------------

Finally, we performed double-immunostaining using an anti-URAT1 antibody and anti-acetylated-α-tubulin antibody as a marker for cilia (Figure [3](#F3){ref-type="fig"}). At high magnification, URAT1 localized to the apical but not to the basolateral membrane of the ependymal cells, which largely co-exist with acetylated-α-tubulin. The absence of URAT1 in the cilia did not affect the localization of acetylated-α-tubulin, indicating that cilia morphology is intact in the knockout mouse. Reminiscent of the URAT1 expression at the apical brush-border membrane of the renal tubular cells, URAT1 localized to the apical membrane including the cilia of ependymal cells.

![**URAT1 localizes at the apical surface of ependymal cells.** Frozen coronal sections from nine-week-old WT and URAT1 KO mice were stained with anti-acetylated-α-tubulin antibody (green), anti-URAT1 antibody (red) and DAPI (blue). The cilia of the ependymal cells lining the D3V were visualized by anti-acetylated-α-tubulin antibody as a cilia marker. Scale bar, 20 μm.](2045-8118-10-31-3){#F3}

Discussion
==========

In the present study, we suggest that the urate transporter URAT1 is involved in UA transport in the ventricular ependymal cells of the mouse brain. Using immunohistochemistry, we showed that URAT1 is expressed on cilia and the apical surface of ependymal cells surrounding the ventricles, and the absence of such staining was confirmed in URAT1 knockout mice. Although URAT1 expression in brain tissues such as brain capillaries, choroid plexus \[[@B14]\], cultured dopaminergic cell lines and astrocytes \[[@B18]\] has been demonstrated by immunoblot analyses, we could not observe comparable expression of URAT1 by immunohistochemical analyses in such regions as we did in ependymal cells. Weaker immunostaining in the brain parenchyma and the choroid plexus were observed in sections from both wild type and knockout mice. Therefore, the band identified by immunoblotting in earlier studies might represent a non-specific binding to a protein other than URAT1. Moreover, earlier studies failed to check whether ependymal cells may have contaminated the brain capillary, choroid plexus or astrocyte samples which were used for immunoblotting. Thus, the expression of URAT1 protein in brain capillaries, choroid plexus or astrocytes has not been verified completely. To our knowledge, this is the first report to demonstrate urate transporter localization in ventricular ependymal cells.

Ependymal cells are single-layered ciliated epithelial cells lining the ventricular surface of the central nervous system, and act as the brain-CSF interface. This site is responsible for the exchange of substances between CSF and extracellular fluid in the neuropile \[[@B19]\]. Since URAT1 transports UA via a mechanism involving the exchange of lactate \[[@B8]\], we propose a novel mechanism in which UA in the CSF is absorbed intracellularly by ependymal cells in the presence of an outwardly-directed lactate gradient. There are two conceivable possibilities for the formation of this lactate gradient. As in the renal tubular cells, a lactate gradient can be formed by the sodium-coupled monocarboxylate transporters SMCT1 and SMCT2, which collectively facilitate the reabsorption of UA via URAT1 \[[@B20]\]. However, the expression of SMCT1 and SMCT2 have only been demonstrated in neurons and Muller glial cells, respectively \[[@B21],[@B22]\], and the expression and possible involvement of SMCTs in ependymal cells remains unknown. Alternatively, the difference in basal lactate concentration between CSF and ependymal cells may be important. Both human and rat data show that lactate concentration is higher in brain ECF (2--5 mM) compared to that in blood (1--2 mM) \[[@B23]\]. In humans, levels of CSF lactate range from 2.0 to 2.7 mM \[[@B24]\]. Since other lactate transporter proteins, referred to as MCT1, MCT2 and MCT4 (monocarboxylate transporter 1, 2 and 4), have been identified in ependymal cells, probably on the basolateral side \[[@B25]-[@B29]\], the lactate levels in ependymal cells may be equivalent to those of brain parenchyma, and thus likely to be higher than CSF lactate. Further analysis regarding the formation of a lactate gradient would be essential in understanding the UA transporting function of URAT1 in ependymal cells.

One outstanding question is how UA might function following incorporation into ependymal cells. One possibility is that intracellular UA may act as an antioxidant and maintain the redox state of ependymal cells. These cells have been shown to contain high levels of glutathione (GSH) \[[@B30]\], a major antioxidant in the CNS, suggesting a need for antioxidant mechanisms. Intriguingly, in the ventral third ventricle, we observed positive staining of URAT1 only in ciliated ependymal cells, but not in the tanycytes, which are non-ciliated cells lining the lower part of the ventral third ventricle. Intracellular uptake of UA may thus be important for the specific function of ciliated-ependymal cells such as ciliary beating, an essential mechanism for proper CSF flow \[[@B31]\].

Another possibility is that UA incorporated into the ependymal cells is further transported into the brain parenchyma. The fact that we detected strong URAT1 expression in ependymal cells may indicate a novel trans-cellular transport mechanism for UA across ependymal cells. This is reminiscent of the UA transport system in the proximal renal tubular cells, in which UA is reabsorbed by URAT1 in the apical membrane and effluxed by URATv1/Glut9 in the basolateral membrane. If urate efflux transporters exist on the basolateral side of ependymal cells, then it is possible that CSF-derived UA could pass through the brain parenchyma and be finally incorporated into neurons and/or astrocytes. One could speculate that UA transport may occur at the blood--brain barrier (BBB). However, the provision of UA from blood to brain parenchyma seems unlikely, since at this point, immunohistochemical data indicate that the urate efflux transporter ABCG2 is the sole UA transporter localized on the luminal side of brain capillaries \[[@B13]\]. Collectively, the URAT1-mediated transport of UA via ependymal cells represents a promising candidate for a key molecule involved in the regulation of UA homeostasis in the brain.

Based on epidemiological and clinical data showing that higher UA levels are associated with reduced risk and slower progression of PD, UA-elevating strategies have emerged as a potential therapy for PD \[[@B5]\]. Furthermore, attenuated neurodegeneration has been demonstrated in animal models of PD which showed increased levels of UA in response to the genetic manipulation of the UA-degrading enzyme, urate oxidase \[[@B3]\], or by UA injection \[[@B4]\], providing a convincing rationale for UA elevation. However, systemic elevation of UA is clearly pathogenic and the benefit-risk ratio of a therapeutic UA-elevating strategy remains uncertain. If the UA transport activity of URAT1 in ependymal cells is critical for the provision of UA to the brain, then the selective facilitation of URAT1 activity, and/or up-regulation of ependymal URAT1 expression in the brain, may be a beneficial strategy for developing UA-based therapy against neurodegenerative diseases.

Conclusions
===========

Our data suggests that the urate transporter URAT1 is expressed on cilia and the apical surface of ventricular ependymal cells in mouse brain. Ependymal URAT1 may thus be involved in a novel UA transport mechanism between CSF and brain parenchyma.
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